A Biogen Idec lab technician
Suzanne Kreiter | The Boston Globe | Getty Images
Biotechnology stocks are emerging as the standout performers in October.
Last week, Biogen’s stock soared after the drugmaker announced it was seeking regulatory approval for an Alzheimer’s drug, aducanumab. The announcement came just months after Biogen discontinued clinical studies of the same…